Hangzhou Huadong Medicine Group Pharmaceutical Research Institute

Hangzhou Huadong Medicine Group Pharmaceutical Research Institute serves as the primary research and development arm of Huadong Medicine, a prominent Chinese pharmaceutical corporation. The institute specializes in the discovery and clinical development of innovative therapies, with a strategic emphasis on oncology, endocrinology, and immunology. Its portfolio includes a robust pipeline of GLP-1 receptor agonists for metabolic diseases and a sophisticated antibody-drug conjugate (ADC) platform. Through extensive international collaborations and internal R&D, the institute drives the company's expansion into global markets and high-growth therapeutic sectors like medical aesthetics and nephrology.